The therapeutic landscape of non-alcoholic steatohepatitis

Detalhes bibliográficos
Autor(a) principal: Perazzo, Hugo
Data de Publicação: 2016
Outros Autores: Dufour, J. F.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/34356
Resumo: 2020-07-23
id CRUZ_6d5c749880984864f03e7d58db64109e
oai_identifier_str oai:www.arca.fiocruz.br:icict/34356
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Perazzo, HugoDufour, J. F.2019-07-23T15:07:29Z2019-07-23T15:07:29Z2016PERAZZO, Hugo; DUFOUR, Jean‐François. The therapeutic landscape of non-alcoholic steatohepatitis. Liver International, v. 37, p. 634-647, 2016.1478-3223https://www.arca.fiocruz.br/handle/icict/3435610.1111/liv.132701478-3231engJohn Wiley and SonsThe therapeutic landscape of non-alcoholic steatohepatitisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-07-23Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.University of Bern. Inselspital. University Clinic for Visceral Surgery and Medicine. Bern, Switzerland / University of Bern. Department of Clinical Research. Hepatology. Bern, Switzerland.Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and hepatocellular ballooning, and may be associated with liver fibrosis leading to cirrhosis and its complications. A pharmacological approach is necessary to treat NASH because of failure to change dietary habits and lifestyle in most patients. Insulin resistance with an increased release of free fatty acids, oxidative stress and activation of inflammatory cytokines seem to be key features for disease progression. Thiazolidinediones, such as pioglitazone and antioxidant agents, such as vitamin E, were the first pharmacological options to be evaluated for NASH. In recent years, several new molecules that target different pathways related to NASH pathogenesis, such as liver metabolic homeostasis, inflammation, oxidative stress and fibrosis, have been developed. Obeticholic acid (INT-747) and elafibranor (GFT-505) have provided promising results in phase IIb, randomized, placebo-controlled clinical trials and they are being evaluated in ongoing phase III studies. Most of the potential treatments for NASH are under investigation in phase II studies, with some at phase I. This diversity in possible treatments calls for a better understanding of NASH in order to enrich trial populations with patients more susceptible to progress and to respond. This manuscript aims to review the pharmacological NASH treatment landscape.Fatty liverFibrosisPharmacological treatmenSteatohepatitisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/34356/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALve_Perazzo_Hugo_etal_INI_2017.pdfve_Perazzo_Hugo_etal_INI_2017.pdfapplication/pdf610895https://www.arca.fiocruz.br/bitstream/icict/34356/2/ve_Perazzo_Hugo_etal_INI_2017.pdfd03a8a8a5a1a5300d2c0e2b214dda493MD52TEXTve_Perazzo_Hugo_etal_INI_2017.pdf.txtve_Perazzo_Hugo_etal_INI_2017.pdf.txtExtracted texttext/plain74103https://www.arca.fiocruz.br/bitstream/icict/34356/3/ve_Perazzo_Hugo_etal_INI_2017.pdf.txtf190a27be1231fcd254c1f6f9a9bb539MD53icict/343562021-03-24 16:32:34.501oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:34Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv The therapeutic landscape of non-alcoholic steatohepatitis
title The therapeutic landscape of non-alcoholic steatohepatitis
spellingShingle The therapeutic landscape of non-alcoholic steatohepatitis
Perazzo, Hugo
Fatty liver
Fibrosis
Pharmacological treatmen
Steatohepatitis
title_short The therapeutic landscape of non-alcoholic steatohepatitis
title_full The therapeutic landscape of non-alcoholic steatohepatitis
title_fullStr The therapeutic landscape of non-alcoholic steatohepatitis
title_full_unstemmed The therapeutic landscape of non-alcoholic steatohepatitis
title_sort The therapeutic landscape of non-alcoholic steatohepatitis
author Perazzo, Hugo
author_facet Perazzo, Hugo
Dufour, J. F.
author_role author
author2 Dufour, J. F.
author2_role author
dc.contributor.author.fl_str_mv Perazzo, Hugo
Dufour, J. F.
dc.subject.en.pt_BR.fl_str_mv Fatty liver
Fibrosis
Pharmacological treatmen
Steatohepatitis
topic Fatty liver
Fibrosis
Pharmacological treatmen
Steatohepatitis
description 2020-07-23
publishDate 2016
dc.date.issued.fl_str_mv 2016
dc.date.accessioned.fl_str_mv 2019-07-23T15:07:29Z
dc.date.available.fl_str_mv 2019-07-23T15:07:29Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv PERAZZO, Hugo; DUFOUR, Jean‐François. The therapeutic landscape of non-alcoholic steatohepatitis. Liver International, v. 37, p. 634-647, 2016.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/34356
dc.identifier.issn.pt_BR.fl_str_mv 1478-3223
dc.identifier.doi.none.fl_str_mv 10.1111/liv.13270
dc.identifier.eissn.none.fl_str_mv 1478-3231
identifier_str_mv PERAZZO, Hugo; DUFOUR, Jean‐François. The therapeutic landscape of non-alcoholic steatohepatitis. Liver International, v. 37, p. 634-647, 2016.
1478-3223
10.1111/liv.13270
1478-3231
url https://www.arca.fiocruz.br/handle/icict/34356
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv John Wiley and Sons
publisher.none.fl_str_mv John Wiley and Sons
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/34356/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/34356/2/ve_Perazzo_Hugo_etal_INI_2017.pdf
https://www.arca.fiocruz.br/bitstream/icict/34356/3/ve_Perazzo_Hugo_etal_INI_2017.pdf.txt
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
d03a8a8a5a1a5300d2c0e2b214dda493
f190a27be1231fcd254c1f6f9a9bb539
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325026267594752

Registros relacionados